Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2021-12-21 Board/Management Inform…
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and resignation of an outside director (사외이사). This type of disclosure specifically concerns changes in the company's board of directors, which falls under the 'Board/Management Information' category.
2021-12-21 Korean
투자판단관련주요경영사항(전이성 췌장암 환자 대상 ivaltinostat/capecitabine 병용요법 또는 capecitabine 단독요법 투여 비교 평가하기 위한 미국 2상 임상시험계획 (IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from CrystalGenomics regarding a 'Major Management Matter' (주요경영사항), specifically the submission of an Investigational New Drug (IND) application to the US FDA for a Phase 2 clinical trial. This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market (DART system). Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2021-12-20 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and details the outcomes of voting items (agenda items) such as the appointment of directors and auditors. This falls directly under the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2021-12-20 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) issued by CrystalGenomics Inc. It includes details about the meeting date, location, agenda items (such as board appointments and articles of incorporation changes), and information regarding electronic voting. This document is a standard proxy solicitation and meeting notice sent to shareholders to inform them of upcoming votes, which fits the 'Proxy Solicitation & Information Statement' category.
2021-12-07 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and is a formal filing submitted to the Financial Services Commission/Korea Exchange. It contains detailed information regarding an upcoming Extraordinary General Meeting (EGM), including the agenda (amendment of articles of incorporation, appointment of directors and auditors), proxy solicitation details, and candidate profiles. This document is a standard proxy solicitation statement used to request shareholder votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2021-12-07 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing from CrystalGenomics regarding the 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의). It details the agenda for an upcoming Extraordinary General Meeting, including the appointment of directors and auditors. While it relates to shareholder meetings, it is a formal notice of the meeting's agenda and logistics rather than the presentation materials used during the meeting (AGM-R) or the final voting results (DVA). It fits best under Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information regarding the meeting's agenda and board nominations.
2021-12-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.